ERIM
JUNO

Eagle Ridge Investment Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Eagle Ridge Investment Management’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5,750
Closed -$253K – 135
2015
Q4 		$253K Hold
5,750
– – 0.06% 107
2015
Q3 		$234K Buy
5,750
+1,000
+21% +$43.9K 0.06% 105
2015
Q2 		$253K Hold
4,750
– – 0.11% 49
2015
Q1 		$288K Buy
+4,750
New +$231K 0.13% 50

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Eagle Ridge Investment Management's JUNO Position: Q1 2016 in Review

Eagle Ridge Investment Management sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2016, closing a stake of 5,750 shares — an estimated $253K sold.

Eagle Ridge Investment Management first reported a position in JUNO in Q1 2015 and held it in 4 quarters. The position peaked at $288K in Q1 2015. 158 funds tracked by Wall St. Rank hold JUNO as of Q1 2016.

  • Eagle Ridge Investment Management reported no remaining Juno Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Eagle Ridge Investment Management sold 5,750 Juno Therapeutics, Inc. shares in Q1 2016, an estimated $253K.
  • Eagle Ridge Investment Management first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 4 quarters.
  • Eagle Ridge Investment Management's Juno Therapeutics, Inc. position peaked at $288K in Q1 2015.
  • 158 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2016.

Based on Eagle Ridge Investment Management's 13F filing for Q1 2016, filed 21 Apr 2016.